Evaluation of the Role of Plasma Biomarkers in the Development of Decompensation in Patients With Cirrhosis .
NCT ID: NCT03084185
Last Updated: 2017-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2012-12-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The duration of the study is 36 months and it provides a cohort of 200 patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
NCT06855056
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041
Acute-On-Chronic Liver Failure In Cirrhotic Patients
NCT04790435
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035
Infections in Hospitalized Cirrhotic Patients
NCT03137719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After randomization, patient will be seen at follow up every 3 months to do blood sample and every 12 months to undergo hepatic vein pressure gradient , according to the guidelines.
In addition, metabolomics analysis will be performed at screening and every 3 months. The results will be analyzed in relation to emergence of decompensation during follow up period, in order to identify specific metabolomics characteristics that may be able to predict decompensation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged between 18 and 75 years
* Obtaining written informed consent
Exclusion Criteria
* Presence of portal vein thrombosis
* HIV
* Liver transplantation
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Modena and Reggio Emilia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ERICA VILLA
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ERICA VILLA, MD
Role: PRINCIPAL_INVESTIGATOR
University of Modena and Reggio Emilia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliera Universitaria Policlinico Di Modena
Modena, MO, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HVPG_HCV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.